Deerfield Management Company, L.P. (Series C) Catalyst Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,133,011 shares of CPRX stock, worth $71.8 Million. This represents 1.62% of its overall portfolio holdings.
Number of Shares
3,133,011
Previous 6,229,634
49.71%
Holding current value
$71.8 Million
Previous $124 Million
47.2%
% of portfolio
1.62%
Previous 2.3%
Shares
9 transactions
Others Institutions Holding CPRX
# of Institutions
344Shares Held
98.4MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$429 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$193 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$133 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$69.1 Million0.02% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.96MShares$67.8 Million0.15% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.36B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...